Skip to content

U.S. Food and Drug Administration (FDA) Approves LATISSE™

U.S. Food and Drug Administration (FDA) Approves LATISSE™

Allergan, Inc. announces that the FDA has approved LATISSE (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.  Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. LATISSE is the first and only science-based treatment approved by the FDA to enhance eyelash prominence as measured by increases in length, thickness and darkness of eyelashes.

Full press release  >

U.S. Food and Drug Administration (FDA) Approves LATISSE™

Global in reach. Specialized in focus.

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Our focus fosters deep engagement with medical specialists and we make it our business to listen closely to their needs so that together we can advance patient care. We combine this strategic focus with a diversified approach that enables us to follow our research and development into new specialty areas where unmet needs are significant.

In partnership with the medical community, we bring scientific excellence and rigor to deliver leading products that improve patient outcomes. And, we go above and beyond this to provide education and information, with the highest level of integrity, that helps patients to fully understand the choices available to them and make well-informed treatment decisions with their doctors. We know we are successful when doctors and patients place their trust in our products and our company, when our employees excel and when our efforts make a meaningful difference in the lives of the patients and communities we serve.

We are pleased to offer a number of leading products, including: BOTOX® (Botulinum Toxin Type A), RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution) 0.03%, BOTOX® Cosmetic (Botulinum Toxin Type A), the JUVÉDERM™ family of dermal fillers, and the LAP-BAND® Adjustable Gastric Banding System. Throughout our Web site you can learn more about these and our full portfolio of products.

AGN NYSE
41.19 (-0.3)
Volume 2,198,700

GLOBAL LOCATIONS

Learn about our worldwide locations.

  

NEWS & EVENTS

12.26.08Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
12.26.08Allergan Announces U.S. Food and Drug Administration (FDA) Approval of LATISSE(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
12.05.08FDA Advisory Committee Unanimously Recommends Approval of LATISSE(TM) (Bimatoprost Solution 0.03%) as a Treatment for Hypotrichosis of Eyelashes
More news